avdeev007 Today, we put rare disease concern Amicus Therapeutics (NASDAQ:FOLD) under the spotlight. The shares have recently slid under the $10 a share level, which seems too cheap given the company's revenue growth and movement towards profitability. We dig into recent quarterly results and update our investment analysis on this small-cap name in the paragraphs below. May 2024 Company Presentation Amicus Therapeutics is headquartered in Princeton, NJ. The company's product portfolio starts with Galafold. T ...